This nationwide survey by leading scleroderma specialists examines physical changes which are not life-threatening, but may change physical appearance and cause an emotional impact. A small Canadian study suggests that some children may respond well to a course of methotrexate in combination with glucocorticoids. However, other doctors see risks. Citing disappointing results in their Phase III Trial of the use of human recombinant relaxin to treat scleroderma, Connetics Corporation announced a halt to the trial. The Scleroderma Foundation in no way endorses any drugs or treatments reported on this website.
Information is provided as a resource to be used with discretion.
Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with one's physician to assure proper evaluation and treatment.